Sanofi 3Q Profit, Sales Grew; Raises 2021 Business EPS View
28 Oktober 2021 - 8:05AM
Dow Jones News
By Cecilia Butini
Sanofi SA on Thursday posted higher net profit and sales for the
third quarter compared with the previous year, and raised its
guidance for business earnings per share for the full year.
The French pharma major posted net profit of 2.32 billion euros
($2.69 billion) up from EUR1.95 billion in the same quarter a year
prior, on sales which grew to EUR10.43 billion from EUR9.48 billion
in 2020.
The company said sales growth was driven by the strong
performance of bestselling drug Dupixent, record sales of vaccines,
and business momentum in its consumer healthcare business.
Business net income--a metric which Sanofi uses to indicate
income without certain one-off items--was EUR2.74 billion, an
increase from EUR2.30 billion in the same quarter the previous
year.
Sanofi raised its business EPS guidance for the year and now
expects the metric to grow around 14% at constant exchange rates,
barring unforeseen major adverse events. The company had previously
expected 12% business EPS growth at constant exchange rates.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 28, 2021 01:50 ET (05:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024